PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15788540-0	2005	In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.	Paroxetine	57-67	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	34-40	
15788540-2	2005	Recent data have provided evidence for mechanism-based inactivation of CYP2D6 by paroxetine.	Paroxetine	81-91	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	71-77	
15788540-3	2005	We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.	Paroxetine	77-87	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	54-60	
15788540-3	2005	We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.	Paroxetine	77-87	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	223-229	
15788540-9	2005	In summary, the scaling model for mechanism-based inactivation successfully predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro data.	Paroxetine	145-155	cytochrome P450, family 2, subfamily d, polypeptide 3	Rattus norvegicus	122-128